236 related articles for article (PubMed ID: 16441227)
21. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
22. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
[TBL] [Abstract][Full Text] [Related]
23. A novel C-terminal homologue of Aha1 co-chaperone binds to heat shock protein 90 and stimulates its ATPase activity in Entamoeba histolytica.
Singh M; Shah V; Tatu U
J Mol Biol; 2014 Apr; 426(8):1786-98. PubMed ID: 24486610
[TBL] [Abstract][Full Text] [Related]
24. Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
[TBL] [Abstract][Full Text] [Related]
25. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Isaacs JS
Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
[TBL] [Abstract][Full Text] [Related]
26. HSP90 as a platform for the assembly of more effective cancer chemotherapy.
Whitesell L; Lin NU
Biochim Biophys Acta; 2012 Mar; 1823(3):756-66. PubMed ID: 22222203
[TBL] [Abstract][Full Text] [Related]
27. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
28. Dual inhibition of chaperoning process by taxifolin: molecular dynamics simulation study.
Verma S; Singh A; Mishra A
J Mol Graph Model; 2012 Jul; 37():27-38. PubMed ID: 22609743
[TBL] [Abstract][Full Text] [Related]
29. The Right Tool for the Job: An Overview of Hsp90 Inhibitors.
Koren J; Blagg BSJ
Adv Exp Med Biol; 2020; 1243():135-146. PubMed ID: 32297216
[TBL] [Abstract][Full Text] [Related]
30. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
Karkoulis PK; Stravopodis DJ; Voutsinas GE
Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
[TBL] [Abstract][Full Text] [Related]
31. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
32. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.
Prodromou C
Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736
[TBL] [Abstract][Full Text] [Related]
33. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.
Li J; Soroka J; Buchner J
Biochim Biophys Acta; 2012 Mar; 1823(3):624-35. PubMed ID: 21951723
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy.
Dobrowsky RT
Curr Diab Rep; 2016 Aug; 16(8):71. PubMed ID: 27318486
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
36. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?
Luo W; Rodina A; Chiosis G
BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S7. PubMed ID: 19090995
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting HSP90 to treat cancer: a strategy in evolution.
Whitesell L; Santagata S; Lin NU
Curr Mol Med; 2012 Nov; 12(9):1108-24. PubMed ID: 22804235
[TBL] [Abstract][Full Text] [Related]
38. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update.
Neckers L; Neckers K
Expert Opin Emerg Drugs; 2005 Feb; 10(1):137-49. PubMed ID: 15757409
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.
Reikvam H; Ersvaer E; Bruserud O
Curr Cancer Drug Targets; 2009 Sep; 9(6):761-76. PubMed ID: 19754360
[TBL] [Abstract][Full Text] [Related]
40. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
